SCHEMBL19979294

SCHEMBL19979294

C=CC(=O)OCCOC(=O)c1ncn2c(=O)n(C)nnc12

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.55
PABPC1 P11940 1/20 0.55
KMT2A Q03164 1/20 0.55
CA12 O43570 3/20 0.44
CA1 P00915 3/20 0.44
CA2 P00918 3/20 0.44
CA9 Q16790 3/20 0.44
THRB P10828 2/20 0.36
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
TSHR P16473 5/20 0.34
ALDH1A1 P00352 3/20 0.34
TP53 P04637 2/20 0.34
HIF1A Q16665 2/20 0.34
HSD17B10 Q99714 1/20 0.34
HPGD P15428 1/20 0.32
CYP3A4 P08684 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3854103 0.84 MEN1 (0.61) MEN1PABPC1KMT2ACA12CA1
SCHEMBL19984454 0.81 MEN1 (0.51) MEN1PABPC1KMT2ACA12CA1
SCHEMBL3855876 0.81 MEN1 (0.56) MEN1PABPC1KMT2ACA12CA1
Temozolomide SCHEMBL3739 0.72 MEN1 (1.00) MEN1PABPC1KMT2ACA12CA1
SCHEMBL3850790 0.70 MEN1 (0.55) MEN1PABPC1KMT2ACA12CA1
Temozolomide SCHEMBL16227379 0.68 MEN1 (0.82) MEN1PABPC1KMT2ACA12CA1
SCHEMBL16569258 0.68 MEN1 (0.61) MEN1PABPC1KMT2ACA12CA1
SCHEMBL2709226 0.66 MEN1 (0.63) MEN1PABPC1KMT2ACA12CA1
Ethylene SCHEMBL15163059 0.62 TSHR (0.80) THRBTSHRALDH1A1TP53HIF1A
Ethylene SCHEMBL15163252 0.62 TSHR (0.80) THRBTSHRALDH1A1TP53HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912709-B2 Temozolomide compounds, polymers prepared therefrom, and method of treating a disease UNIVERSITY OF MASSACHUSETTS (US) 2024-02-27 US disclosed
US-11912709-B2 Temozolomide compounds, polymers prepared therefrom, and method of treating a disease UNIVERSITY OF MASSACHUSETTS (US) 2024-02-27 US disclosed
US-20210198265-A1 TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE UNIVERSITY OF MASSACHUSETTS 2021-07-01 US disclosed
US-10995094-B2 Temozolomide compounds, polymers prepared therefrom, and method of treating a disease THE UNIVERSITY OF MASSACHUSETTS (US) 2021-05-04 US disclosed
US-20200140448-A1 TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE NATIONAL SCIENCE FOUNDATION 2020-05-07 US disclosed
US-10562901-B2 Temozolomide compounds, polymers prepared therefrom, and method of treating a disease THE UNIVERSITY OF MASSACHUSETTS (US) 2020-02-18 US disclosed
US-20180079754-A1 TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE NATIONAL SCIENCE FOUNDATION 2018-03-22 US disclosed
US-20180079754-A1 TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE NATIONAL SCIENCE FOUNDATION 2018-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912709-B2 Temozolomide compounds, polymers prepared therefrom, and method of treating a disease PBRM1, MGMT, TOP1 MEN1 5/4885PABPC1 1794/4885KMT2A 401/4885
US-20210198265-A1 TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE PBRM1, MGMT, TOP1 MEN1 5/4885PABPC1 1794/4885KMT2A 401/4885
US-20200140448-A1 TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE PBRM1, MGMT, TOP1 MEN1 5/4885PABPC1 1794/4885KMT2A 401/4885
US-10562901-B2 Temozolomide compounds, polymers prepared therefrom, and method of treating a disease PBRM1, MGMT, TOP1 MEN1 5/4885PABPC1 1794/4885KMT2A 401/4885
US-20180079754-A1 TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE PBRM1, MGMT, TOP1 MEN1 5/4885PABPC1 1794/4885KMT2A 401/4885
US-10995094-B2 Temozolomide compounds, polymers prepared therefrom, and method of treating a disease PBRM1, MGMT, TOP1 MEN1 5/4885PABPC1 1794/4885KMT2A 401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.